News

Factor VIIa is used to treat hemophilia A and B patients who have developed inhibitors against treatment with either Factor VIII or IX and are suferring from acute

With this plan, the company expects to seek approval for an initial indication that includes obese men and women of non-child bearing potential. The company intends to refile

The acquisition allows VBI to develop its own VLP-based vaccines by leveraging its suite of thermostable vaccine formulation technologies. The terms of the deal were not disclosed. VBI

Hyalgan is an injectable treatment for knee pain associated with osteoarthritis when simple painkillers or exercise and physical therapy are not enough. Following the transfer of the rights,

The additional funding is expected to support Cellerant’s CLT-008 development strategy to expand its current clinical trials, process development and manufacturing activities and to fund additional nonclinical studies

The agreement allows Verde to develop products which are designed to adsorb and inactivate the active ingredients in pills, tablets, capsules and topical patches, in a convenient and

Initially, Teva is expected to invest around $7.5m in CDI under which CDI will be responsible to develop an antiviral drug targeting the polymerase enzyme of the Hepatitis

NowClinic offers Rite Aid customers real-time access to convenient medical care, information and resources from doctors and OptumHealth nurses. With this new application, the customers of Rite Aid

Levetiracetam Extended-Release Tablets are the generic version of Keppra XR of UCB. Keppra is an anti-epileptic drug which is indicated for the treatment of partial onset seizures in